Gevorg Yaghjyan: Low Drug Levels, Higher Cardiovascular Risk in Lupus
Gevorg Yaghjyan, Adviser at Intelligent Medical Cloud, Co-Founder of ICPD, shared a post on LinkedIn about a recent article by Rachel Martin, published in Yale School of Medicine, adding:
“Beyond Efficacy: Why Medication Adherence and Drug Exposure Matter in Clinical Development
An important Yale-led study highlights how a well-established therapy may provide benefits beyond controlling the primary disease.
Researchers followed 248 patients with systemic lupus erythematosus and found that very low blood levels of hydroxychloroquine – together with poor medication adherencee – were associated with increased cardiovascular risk over one to two years.
The findings support therapeutic drug monitoring and more individualized dosing strategies rather than a uniform, one-size-fits-all approach.
From a clinical-trial and drug-development perspective, this study reinforces several important principles:
- Clinical outcomes depend not only on the prescribed dose but also on actual drug exposure and sustained adherence.
- Pharmacokinetic and adherence data can help explain variability in treatment response.
- Long-term studies should assess outcomes beyond disease activity, including cardiovascular and other organ-related complications.
- Real-world evidence can uncover additional value from established therapies and inform the design of future prospective trials.
- Patient education and point-of-care monitoring may themselves become meaningful components of treatment optimization.
This is a strong example of how clinical research can move an established medicine toward more personalized, measurable, and outcomes-focused care.”
Title: Adhering to Common Lupus Treatment Lowers Risk of Heart Issues
Authors: Rachel Martin
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke